VIDEO: ‘A lot of potential’ for targeting protein degradation
In this video, Stan Lipkowitz, MD, PhD, chief of the women's malignancies branch in the National Cancer Institute's Center for Cancer Research, discusses new research into targeting protein degradation.
"One of the reasons this is so exciting is, generally, for small molecule inhibitors, we look for things that have catalytic active sites, so if you want to hit a kinase you can use a small molecule inhibitor,” Lipokowitz said. “The problem is there are many proteins where there is not a catalytic domain that you can inhibit; these include transcription factors or other structural proteins. By using the targeted protein degradation, you can start to address them.”
Collapse
Ebert LB, et al. Targeted protein degradation for the treatment of cancer. Presented at: 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (virtual meeting); Oct. 7-10, 2021.
Schulman B, et al. How do Cullin-RING ligases ubiquitylate structurally diverse substrates? Presented at: 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (virtual meeting); Oct. 7-10, 2021.